Takeaways from the East-West Summit

Plus the challenges ahead for new CEOs at Biogen and Seagen

There are clear indicators of the maturation of China’s biotech sector, although East and West biopharma leaders have diverging views on how easy cross-border investment will be going forward, BioCentury’s Editor-in-Chief Simone Fishburn said on the latest BioCentury This Week podcast. Fishburn discussed takeaways from the summit held last week, while Executive Editor Selina Koch reviewed her panel on the optimism R&D leaders have for the future role multi-omics can play in drug development.

BioCentury editors also discussed the recent appointments of Chris Viehbacher as CEO of Biogen Inc. (NASDAQ:BIIB) and David Epstein of Seagen Inc. (NASDAQ:SGEN) and the challenges each face at their respective embattled biotechs.